Marinus Pharmaceuticals, Inc
MRNS
MRNS was delisted on the 10th of February, 2025.
74 hedge funds and large institutions have $131M invested in Marinus Pharmaceuticals, Inc in 2020 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 30 increasing their positions, 12 reducing their positions, and 17 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 12
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
9.54% more ownership
Funds ownership: 64.86% → 74.4% (+9.5%)
8% more capital invested
Capital invested by funds: $121M → $131M (+$9.82M)
6% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 17
6% less funds holding
Funds holding: 79 → 74 (-5)
71% less call options, than puts
Call options by funds: $407K | Put options by funds: $1.41M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JG
Jefferies Group
New York
|
+$4.1M |
| 2 |
BlackRock
New York
|
+$3.33M |
| 3 |
BL
Bleichroeder LP
New York
|
+$2.71M |
| 4 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$2.25M |
| 5 |
JP Morgan Chase
New York
|
+$2.13M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
-$1.76M |
| 2 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$398K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$207K |
| 4 |
AC
Aristides Capital
Louisville,
Kentucky
|
-$177K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$159K |
MRNS Hedge Fund Activity: Q1 2020 in Review
74 of the 4,548 institutional investors tracked by Wall St. Rank reported a position in Marinus Pharmaceuticals, Inc (MRNS) for Q1 2020, worth a combined $131M — up 8.1% from $121M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of MRNS and 16 opened new positions — a net loss of 1 holder — while 12 trimmed existing stakes and 30 added.
The largest buyer was Jefferies Group, opening a new position worth an estimated $4.1M. The largest seller was Granite Point Capital Management, cutting an estimated $1.76M.
- 74 institutional investors held Marinus Pharmaceuticals, Inc (MRNS) as of Q1 2020, down from 79 in Q4 2019.
- Funds reported $131M of Marinus Pharmaceuticals, Inc stock for Q1 2020, up 8.1% quarter-over-quarter.
- 16 funds opened new Marinus Pharmaceuticals, Inc positions in Q1 2020 and 17 closed out, a net change of -1 holder.
- The largest Marinus Pharmaceuticals, Inc buyer in Q1 2020 was Jefferies Group, an estimated $4.1M added.
- The largest Marinus Pharmaceuticals, Inc seller in Q1 2020 was Granite Point Capital Management, an estimated $1.76M sold.
Based on aggregated 13F filings for Q1 2020.